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Abstract
Background: Insulin-degrading enzyme (IDE) is widely recognized as the principal protease responsible for the clearance
and inactivation of insulin, but its role in glycemic control in vivo is poorly understood. We present here the first longitudinal
characterization, to our knowledge, of glucose regulation in mice with pancellular deletion of the IDE gene (IDE-KO mice).
Methodology: IDE-KO mice and wild-type (WT) littermates were characterized at 2, 4, and 6 months of age in terms of body
weight, basal glucose and insulin levels, and insulin and glucose tolerance. Consistent with a functional role for IDE in insulin
clearance, fasting serum insulin levels in IDE-KO mice were found to be ,3-fold higher than those in wild-type (WT) controls
at all ages examined. In agreement with previous observations, 6-mo-old IDE-KO mice exhibited a severe diabetic
phenotype characterized by increased body weight and pronounced glucose and insulin intolerance. In marked contrast, 2-
mo-old IDE-KO mice exhibited multiple signs of improved glycemic control, including lower fasting glucose levels, lower
body mass, and modestly enhanced insulin and glucose tolerance relative to WT controls. Biochemically, the emergence of
the diabetic phenotype in IDE-KO mice correlated with age-dependent reductions in insulin receptor (IR) levels in muscle,
adipose, and liver tissue. Primary adipocytes harvested from 6-mo-old IDE-KO mice also showed functional impairments in
insulin-stimulated glucose uptake.
Conclusions: Our results indicate that the diabetic phenotype in IDE-KO mice is not a primary consequence of IDE
deficiency, but is instead an emergent compensatory response to chronic hyperinsulinemia resulting from complete
deletion of IDE in all tissues throughout life. Significantly, our findings provide new evidence to support the idea that partial
and/or transient inhibition of IDE may constitute a valid approach to the treatment of diabetes.
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Introduction
Following its secretion from the pancreas, circulating insulin
levels are regulated entirely by proteolytic degradation and other
catabolic processes. The degradation and inactivation of insulin,
in turn, is well established to be mediated primarily by insu-
lin-degrading enzyme (IDE), a structurally and evolutionarily
distinctive zinc-metalloprotease [1,2,3,4]. Despite IDE’s central
involvement in insulin metabolism, surprisingly little work has
directly addressed its role in regulating insulin and glucose
homeostasis in vivo. Moreover, the few studies that have inves-
tigated this topic appear to support contradictory conclusions. On
the one hand, IDE’s established role in insulin catabolism predicts
that IDE inhibition should increase the half-life of circulating
insulin, an effect that could be beneficial for the treatment of
diabetes. This idea is supported by a body of work [5] that
emerged following the discovery of IDE in 1949 [6]. Most
compellingly, Mirsky and colleagues demonstrated that a purified
endogenous inhibitor of IDE (non-proteinaceous, but of unknown
identity) could potentiate the hypoglycemic action of insulin in vivo
[7]. On the other hand, recent work in two different animal
models appears to support the contradictory idea that reductions
in IDE activity can in fact induce a diabetic phenotype. First, a
widely used rodent model of diabetes—the Goto-Kakizaki (GK)
rat [8]—was shown to harbor missense mutations in the IDE
gene that decrease the efficiency of insulin degradation [9,10].
Subsequently, mice with homozygous deletion of the IDE gene
(IDE-KO mice) were found to exhibit pronounced glucose
intolerance as well as hyperinsulinemia [4]. The discrepancy
between these animal modeling studies and earlier work suggesting
a beneficial role for reducing IDE activity has not been resolved.
To address this topic, we characterized insulin and glucose
homeostasis in IDE-KO and wild-type (WT) mice longitudinally,
across the first 6 months of life. Confirming earlier work [4], by 6
months of age IDE-KO mice develop pronounced fasting hype-
rinsulinemia and glucose intolerance and, as we now show, signi-
ficant insulin intolerance, fasting hyperglycemia and increased
body mass. In striking contrast, at 2 months of age IDE-KO mice
were significantly improved relative to WT controls in terms of
virtually all parameters tested, including body mass, fasting blood
glucose, as well as glucose and insulin tolerance, while showing the
same degree of hyperinsulinemia as 6-mo-old IDE-KO mice.
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KO mice exhibited reductions in insulin receptor (IR) levels and/
or function in multiple tissues that, like the diabetic phenotype
itself, emerged in an age-dependent manner. These results suggest
that the diabetic phenotype in IDE-KO mice emerges as a
compensatory adaptation to chronic hyperinsulinemia induced by
complete, pan-cellular deletion of IDE throughout life. The
implications of these findings for the pathogenesis of type 2
diabetes and for the therapeutic potential of IDE inhibition are
discussed.
Results
To elucidate the consequences of IDE deficiency on glycemic
regulation in vivo, we investigated insulin and glucose homeostasis
in male IDE-KO mice and WT littermates backcrossed into a
pure C57Bl/6J genetic background. We used a longitudinal
design, in which a single group of animals was monitored
repeatedly at 3 successive ages (2, 4 and 6 months) in terms of
multiple diabetes-relevant parameters. For biochemical analyses, a
separate set of mice was harvested cross-sectionally, at 2 and 6
months of age.
As expected given the known role of IDE in insulin catabolism,
and consistent with previous findings [4], fasting serum insulin
levels in IDE-KO mice were found to be approximately 3-fold
higher than those in WT controls at all ages examined (Fig. 1). By
contrast, the effects of IDE deficiency on virtually all other
parameters varied in an age-dependent manner. Relative to age-
matched controls, basal glucose levels were significantly lower in 2-
mo-old IDE-KO mice, unchanged in 4-mo-old animals, and
significantly increased in 6-mo-old IDE-KO mice (Fig. 2A). Body
mass followed a corresponding trend, with 2-mo-old IDE-KO
mice being significantly lighter, and 6-mo-old IDE-KO mice
significantly heavier, than age-matched WT controls (Fig. 2B).
The emergence of the diabetic phenotype induced by IDE
deletion [4] was monitored by performing glucose and insulin
tolerance tests at 2, 4 and 6 months of age. Corroborating previous
results [4], at 6 months of age IDE-KO mice exhibited profound
glucose intolerance, with mean blood glucose levels induced by
intraperitoneal injection of D-glucose (1 g/kg) approaching
400 mg/dL by 30 min as compared to 200 mg/dL for WT mice
(Fig. 3C). By contrast, at 2 months of age IDE-KO mice not only
lacked glucose intolerance but in fact exhibited modest but
statistically significant improvements in glucose disposal (Fig. 3A).
Consistent with an age-dependent transition from improved to
impaired glucose tolerance, 4-mo-old IDE-KO mice showed an
intermediate phenotype (Fig. 3B). In terms of insulin tolerance, the
IDE-KO mice were significantly intolerant at 6 months (Fig. 3F),
but largely normal at 4 months of age relative to age-matched
controls (Fig. 3E). Notably, 2-mo-old IDE-KO mice showed
statistically significant improvements in insulin tolerance relative to
WT littermate controls (Fig. 3D).
The preceding results suggest that the diabetic phenotype in
older IDE-KO mice may represent a compensatory response to
chronically elevated circulating insulin. To explore this idea at a
biochemical level, tissues were harvested from a separate set of
mice at 2 and 6 months of age. Based on evidence from other
animal models of hyperinsulinemia [11,12,13] (see below), we
focused on insulin receptor (IR) levels, which were quantified in
Figure 1. Constitutive hyperinsulinemia in IDE-KO mice. Insulin
levels in serum of 2-, 4- and 6-mo-old wild-type (WT) and IDE-KO (KO)
mice following overnight fasting. Data are mean 6 SEM of 10–12 mice
per group. *P,0.05 determined by 2-tailed Student’s t test.
doi:10.1371/journal.pone.0020818.g001
Figure 2. Age-dependent changes in basal blood glucose and
body weight. A, Blood glucose in 2-, 4- and 6-mo-old wild-type (WT)
and IDE-KO (KO) mice following overnight fasting. Note that 2-mo-old
IDE-KO mice exhibit significantly lower basal glucose levels relative to
controls. B, Body weight of fasted 2-, 4- and 6-mo-old WT and IDE-KO
mice. Note that IDE-KO mice weigh significantly less than wild-type
controls mice at 2 months yet significantly more at 6 months of age.
Data are mean 6 SEM of 10–12 mice per group. *P,0.05 IDE-KO vs. WT
as determined by 2-tailed Student’s t test.
doi:10.1371/journal.pone.0020818.g002
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of insulin. At 2 months of age, WT and IDE-KO mice exhibited
comparable IR levels in all tissues examined (Fig. 4A–C). IR levels
also did not change significantly between 2 and 6 months of age in
any tissues from WT mice (Fig. 4A–C). In marked contrast, 6-mo-
old IDE-KO mice showed significant reductions in total IR levels
in all tissues examined, including muscle (Fig. 4A), adipose tissue
(Fig. 4B) and liver (Fig. 4C).
To determine whether these biochemical perturbations were
associated with functional changes to glucose transport, we
conducted glucose uptake assays in primary adipocytes isolated
from 6-mo-old IDE-KO and WT mice. Consistent with the
reduction in IR levels observed by western blotting, IDE-KO
adipocytes showed substantial impairments in insulin-stimulated
glucose uptake (Fig. 4D).
Discussion
In the present study, we investigated glucose homeostasis in
mice lacking IDE, the principal protease involved in the clearance
and inactivation of insulin [15], across the first 6 months of life.
Consistent with its known functional role, IDE deficiency led to
significant hyperinsulinemia at all ages examined (2, 4, and 6
months). However, the elimination of IDE-mediated insulin
catabolism had remarkably different consequences for glucose
homeostasis at different ages. In the youngest animals studied, IDE
deficiency led to modestly improved glycemic control and dec-
reased body weight, a phenotype that is consistent with earlier
experimental findings showing that IDE inhibition enhances the
hypoglycemic action of insulin in vivo [7,16]. On the other hand, as
the IDE-KO animals aged, they showed progressively poorer
glycemic control, culminating in profound glucose and insulin
intolerance. These metabolic disturbances correlated with age-
dependent decreases in IR levels in multiple tissues, together with
functional impairments in IR-mediated glucose uptake.
Taken together, these findings have significant implications for
both the etiology and the potential treatment of diabetes. In terms
of diabetes pathogenesis, our results corroborate several studies
suggesting that insulin resistance can arise as a secondary
consequence of primary persistent hyperinsulinemia. For instance,
repeated administration of insulin (up to 6U/day) to rats over a 2-
week period led to reductions in both maximal insulin binding
capacity and IR-mediated glucose utilization [11]. Moreover, a 4-
week period of hyperinsulinemia induced by surgical diversion of
pancreatic veins from the portal vein to the vena cava in dogs
resulted in significant reductions in the glucose disposal rate that
were associated with reduced IR activity [12]. Furthermore,
hyperinsulinemia induced by transgenic overexpression of human
insulin has been reported to result in impaired glucose tolerance
[13]. Taken together with our own findings in IDE-KO mice, this
body of work strongly suggests that, if sufficient in magnitude and
duration, chronic hyperinsulinemia per se can be a primary cause of
insulin resistance. Mechanistically, in light of the finding that IR
levels and/or activity are significantly reduced in IDE-KO mice
and multiple other models of chronic hyperinsulinemia, we
speculate that insulin insensitivity may, in part, result from classic
receptor down-regulation—i.e., adaptation to chronically elevated
insulin levels.
While the disturbances in IR levels and functionality we
observed appear to offer a neat explanation for the emergence of
the diabetic phenotype in IDE-KO mice, we emphasize that
considerably more study will be required before firm conclusions
can be made. For example, until a more comprehensive analysis is
conducted, we cannot formally exclude the possibility that deletion
Figure 3. Age-dependent emergence of the diabetic phenotype in IDE-KO mice. A–C, Glucose tolerance tests in 2- (A), 4-(B), and 6-mo-old
(C) wild-type (WT) and IDE-KO (KO) mice. Note that 2-mo-old IDE-KO mice exhibit improved glucose tolerance at some time points. Data are mean 6
s.d. of 10–12 mice per condition. *P,0.05. D–F, Insulin tolerance tests in 2- (D), 4-(E), and 6-mo-old (F) WT (WT) and IDE-KO (KO) mice. Note the trend
towards improved insulin tolerance in 2-mo-old IDE-KO mice. Data are mean 6 s.d. of 10–12 mice per condition. *P,0.05 IDE-KO vs. WT as
determined by 2-tailed Student’s t test.
doi:10.1371/journal.pone.0020818.g003
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turn elicit compensatory hyperinsulinemia. Given that IDE is
known to degrade other substrates involved in glucose homeostasis
and diabetes pathogenesis, including glucagon [17] and amylin
[18], this question merits further investigation.
The reduction in liver IR levels seen in IDE-KO mice are of
special interest, because clearance of circulating insulin, which
occurs primarily in liver, is initiated and rate-limited by IR-
mediated internalization [3]. Given this functional role, reductions
in liver IR levels would be predicted to result in impaired insulin
clearance and increased basal insulin levels. Because both of these
disturbances are hallmark features of type 2 diabetes, liver IR
levels may represent a critical factor in the etiology and potential
treatment of these aspects of the disease. It is relevant to note in
this context that, in immortalized IDE-KO hepatocytes main-
tained in culture for multiple passages, IR levels were found to be
dramatically increased (,8-fold) relative to WT hepatocytes, with
the population of cell-surface IR elevated still further (,40-fold;
J.Z. and M.A.L., unpublished observations). While a comparable
effect was not observed in vivo, this observation implies that hepatic
IR levels are indeed regulated by IDE-dependent factors that, if
identified, could potentially be exploited to modulate insulin
clearance.
The precise mechanisms underlying the enhancement of insulin
signaling induced by transient reductions in IDE are presently
unclear. Superficially, this effect might appear to exclusively derive
from the slowing of insulin clearance from the circulation (see Ref.
5). However, recent evidence suggests that suppression of IDE
activity can also enhance insulin signaling subsequent to the
binding of insulin to the IR [19], suggesting that processes occ-
urring at the level of destination cells may be operative either
alternatively or in addition to effects on circulating insulin. More
work will be needed to clarify the relative contributions of these
two possible mechanisms.
From a therapeutic perspective, our results support the idea that
pharmacologic inhibition of IDE, properly implemented, may
represent a viable—even attractive—therapeutic approach to the
treatment of diabetes. In terms of effects on insulin signaling, a
short-acting, partial inhibitor of IDE would be predicted to exert
similar effects as sulfonylureas or similar secretagogues—namely,
increasing the area under the curve of circulating insulin, while
maintaining normal rhythmicity of secretion. It is fascinating to
note in this context that the sulfonylureas were originally believed
to act by inhibiting IDE [20]. To the extent that IDE inhibitors
and secretagogues both act by increasing circulating insulin, the
mechanism-based risk-benefit profile of both would likely be
similar. However, IDE inhibitors might hold certain advantages
over secretagogues, for they would not be predicted to affect
pancreatic function per se. Moreover, the risks from overdose of
an IDE inhibitor would appear to be minimal, since complete
Figure 4. IDE-KO mice show age-dependent reductions in IR levels and insulin-stimulated glucose uptake that correlate with the
onset of the diabetic phenotype. A–C, IR levels in muscle (A) adipose (B) and liver (C) tissue from wild-type (WT) and IDE-KO (KO) mice. Note that
IR levels in IDE-KO mice are significantly decreased in all tissues at 6 months, but not at 2 months of age. Graphs show mean 6 SEM of IR levels
quantified by luminescent imaging (see Materials and Methods) and normalized to IR levels in 2-mo-old WT mice. *P,0.05 relative to 6-mo-old WT
mice;
#P,0.01 relative to 2-mo-old KO mice and P,0.05 relative to 6-mo-old WT and KO mice;
XP,0.05 relative to 2-mo-old KO mice, all determined
by 2-tailed Student’s t tests. D, Insulin-stimulated glucose uptake is significantly impaired in primary adipocytes isolated from 6-mo-old IDE-KO mice.
Quantification was performed by measuring cellular uptake of
14C-deoxyglucose (
14C-DOG) various times after addition of insulin (16.7 nM). Data are
mean of 2 independent experiments utilizing epididymal adipose tissue collected from 4 mice per condition for each replication.
doi:10.1371/journal.pone.0020818.g004
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quences [4]. This compares favorably with many other anti-
diabetic medications that can be harmful or even lethal if taken in
excess [21]. It is relevant to note in this context that our laboratory
recently succeeded in developing peptide hydroxamate IDE
inhibitors, which represent the first potent and selective small-
molecule inhibitors of IDE or indeed any other member of this
unusual protease superfamily [19]. We are actively working to
generate improved versions of these first-generation IDE inhibitors
sufficiently stable for use in vivo, which will permit a direct test of
the anti-diabetic potential of this important new class of protease
inhibitor.
In conclusion, our analysis of IDE-KO mice suggests a natural
resolution to the conflicting ideas concerning the consequences of
IDE inhibition for glucose homeostasis in vivo: by virtue of IDE’s
role in insulin catabolism, short-term and/or partial inhibition of
IDE is expected to enhance the hypoglycemic action of insulin, an
effect that in principle could be beneficial for the treatment of
diabetes. Conversely, sustained, complete inhibition of IDE in all
tissues, by inducing chronic hyperinsulinemia, elicits compensato-
ry changes to insulin signaling that contribute to insulin
intolerance and, hence, glucose intolerance. Given the beneficial
effects of transient inhibition of IDE on glycemic control observed
in this study, pharmacological inhibition of IDE would appear to
represent a potentially viable approach to the treatment of
diabetes that merits more thorough evaluation in the future.
Materials and Methods
Animals
Founder IDE
+/2 mice were obtained from the Mutant Mouse
Regional Resource Center then backcrossed into the C57Bl6/J
background for 9 generations prior to initiation of the study. Mice
were fed Teklad S-2335 mouse breeder chow (Harlan Laborato-
ries, Indianapolis, IN) and males were used for all experiments.
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee of
Mayo Clinic Jacksonville (Protocol Number A16810). All efforts
were made to minimize suffering.
Insulin and glucose measurements
Serum insulin levels were determined using the HTRFH Insulin
Assay (CisBio, Bedford, MA) and detected using a SpectraMax
M5e microplate reader (Molecular Devices, Inc., Sunnyvale, CA)
according to manufacturers’ recommendations. Blood glucose
levels were measured using the AscenciaH ELITEH SL Blood
Glucose Monitoring System (Bayer HealthCare, Tarrytown, NY)
according to manufacturer’s recommendations. Glucose and
insulin tolerance tests were conducted by monitoring blood
glucose following i.p. administration of D-glucose (1 g/kg) or
human insulin (1 U/kg), respectively. All measurements were
obtained from tail blood samples of mice fasted for 6 to 9 h.
Western blotting
Western blots were performed as described [22] using protein
extracts (8 mg/well) from muscle, adipose and liver tissue.
Antibodies and dilutions used included anti-Insulin Receptor
(1:1000; Cell Signaling Technology, Danvers, MA), and anti-
GAPDH (1:10,000; BioDesign, Inc., Carmel, NY). Western blots
of IR and loading controls were quantified using a LAS-4000
Luminescent Image Analyzer equipped with a 3.2-megapixel
CCD camera and its associated software (MultiGauge v. 3.1)
according to manufacturer’s recommendations (Fujifilm Life-
science, Greenwood, SC).
Glucose uptake assays
Glucose uptake assays were performed in primary adipocytes
isolated from epididymal fat pads essentially as described [23].
Briefly, dissociated adipocytes were incubated in KRBH buffer
(120 mM NaCl, 4 mM KH2PO4, 2 mM CaCl2, 1 mM MgSO4,
30 mM HEPES, pH 7.4) supplemented with adenosine (200 nM).
Glucose uptake was assessed by addition of KRBH buffer
supplemented with 2.5 mM 2-D-glucose, 1% BSA, and 1 mM
14C-deoxy-D-glucose (
14C-DOG; Perkin Elmer, Waltham, MA)
following stimulation with human recombinant insulin (16.7 nM).
Reactions were incubated at 37uC and terminated by addition
of cytochalasin B. Following partitioning of cellular contents
in dinoyl phthalate, radioactivity in the non-aqueous layer was
counted using a liquid scintillation counter (Beckman Coulter).
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